SUBCUTANEOUS APOMORPHINE ADMINISTRATION IN PARKINSONIAN MOTOR FLUCTUATIONS
- 1 January 1990
- journal article
- research article
- Vol. 146 (2) , 116-122
Abstract
Apomorphine, a dopaminergic agonist was given over a period of 12 months to 14 parkinsonian patients suffering from severe L-dopa induced on-off effects. Nine patients (mean age: 52 years; mean age at onset of the disease: 37 years), were treated by continuous infusion with a portable minipump, and 5 others by multiple injections with a penject. The mean duration of daily off periods was reduced by two thirds in all patients. The motor fluctuation intensity was only diminished in the 9 patients treated by continuous infusion. These patients received a mean apomorphine daily dose of 93 mg and L-dopa dosage was reduced by 53 p. 100. Red fibrous subcutaneous nodules occurred at the injection sites in all patients treated by infusion. This study confirms the effectiveness of subcutaneous apomorphine administration in the treatment of severe motor flutuations.This publication has 14 references indexed in Scilit:
- Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage intervalPsychopharmacology, 1985
- Control of on/off phenomenon by continuous intravenous infusion of levodopaNeurology, 1984
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984
- A comparison of the behavioural consequences of chronic stimulation of dopamine receptors in the nucleus accumbens of rat brain effected by a continuous infusion or by single daily injectionsNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1983
- 3‐O‐Methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathwayNeurology, 1982
- Fluctuations of disability in Parkinson's disease – clinical aspectsPublished by Elsevier ,1981
- Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapyNeurology, 1979
- THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASEThe Lancet, 1979
- BROMOCRIPTINE ASSOCIATED WITH A PERIPHERAL DOPAMINE BLOCKING AGENT IN TREATMENT OF PARKINSON'S DISEASEThe Lancet, 1979
- Treatment of Parkinson's Disease with AporphinesNew England Journal of Medicine, 1976